Form 4: Arrowhead CFO Granted 75,000 Restricted Stock Units

Arrowhead Pharmaceuticals' Chief Financial Officer, Daniel Joseph Apel, was granted 75,000 restricted stock units, increasing his beneficial ownership to 176,200 shares.

Summary

• Daniel Joseph Apel, Chief Financial Officer of ARROWHEAD PHARMACEUTICALS, INC. (ARWR), acquired 75,000 shares of common stock.
• The acquisition was made on January 6, 2026, at a price of $0 per share, representing a grant of restricted stock units (RSUs).
• These RSUs will vest in four equal annual installments.
• Following this transaction, Mr. Apel beneficially owns 176,200 shares of common stock.
• The reported beneficial ownership includes previously reported shares of common stock underlying Restricted Stock Units, a portion of which are still subject to certain vesting conditions.

Sentiment

Score: 6

Explanation: The grant of restricted stock units to a key executive is generally a neutral to slightly positive event, as it aligns management incentives with shareholder interests, but does not directly reflect operational performance or new strategic developments.

Positives

• The grant of restricted stock units aligns the Chief Financial Officer's long-term interests with those of shareholders, incentivizing performance.
• The increase in beneficial ownership by a key executive demonstrates continued commitment to the company.

Risks

• The 75,000 restricted stock units are subject to vesting conditions, meaning the reporting person does not fully own these shares until the vesting schedule is met.

Future Outlook

The filing indicates that the newly granted restricted stock units will vest in four equal annual installments, suggesting a long-term incentive structure for the Chief Financial Officer.

Industry Context

This is a routine insider transaction filing for executive compensation in the biotechnology and pharmaceutical industry, where equity grants like restricted stock units are common practice to attract, retain, and incentivize key management personnel.

Comparison to Industry Standards

• The grant of restricted stock units as part of executive compensation is a standard practice across the biotechnology and pharmaceutical sectors, aligning executive incentives with long-term shareholder value creation.
• The vesting schedule of four equal annual installments is a common structure for such grants, promoting retention and sustained performance over several years, comparable to practices at companies like Moderna or Pfizer for similar executive roles.

Stakeholder Impact

• Shareholders: The grant of RSUs to the CFO can be viewed positively as it aligns management's financial interests with the company's long-term performance, potentially leading to better shareholder returns.
• Employees: This filing primarily concerns executive compensation and does not directly impact the broader employee base, though it reflects the company's compensation philosophy for leadership.

Next Steps

• The restricted stock units will vest in four equal annual installments, beginning at a future date not specified beyond the transaction date.

Key Dates

Keywords

ARWR, Arrowhead Pharmaceuticals, Form 4, Restricted Stock Units, RSU Grant, Insider Transaction, Daniel Joseph Apel, CFO